LONDON—U.S. drug maker AbbVie Inc. is close to clinching a deal to buy Dublin-based Shire PLC for more than £31 billion ($53.6 billion), in what would be one of the largest so-called inversion deals through which U.S. companies are seeking a lower corporate tax burden.. After four days of renewed talks between the two drug makers, Shire said Monday it had received a revised offer from AbbVie of £53.20 a share over the weekend. Shire said it would be willing to recommend the deal to its shareholders subject to "satisfactory...
  